摘要
目的评估高迁移率族蛋白B1(HMGB1)在人脑胶质瘤组织中的表达及临床意义。方法通过检索Pub Med、Embase、Ovid、中国期刊网全文数据库(CNKI)和万方等数据库,获取关于HMGB1和胶质瘤关系的文献,根据纳入与排除标准将最后筛选出的文献使用Revman 5.3软件进行Meta分析。结果最终纳入7篇符合标准文献,共576例患者,Meta分析结果显示:胶质瘤和对照组HMGB1表达的差异采用检测方法免疫组织化学法(IHC)[优势比(OR)=26.53;95%可信区间(CI)=13.70~51.35;P<0.01]和实时荧光定量聚合酶链式反应(RT-PCR)[均数差(MD)=16.55;95%CI=11.21~21.90;P<0.01]、HMGB1表达与胶质瘤病理分级关系的表达差异(OR=0.53;95%CI=0.31~0.90;P=0.02)均有统计学意义,而HMGB1表达与胶质瘤是否伴有癫痫(OR=5.32;95%CI=0.10~293.11;P=0.41)差异无统计学意义。结论 HMGB1表达相比对照组胶质瘤中的显著升高,且与胶质瘤病理分级相关,提示HMGB1有望应用作为胶质瘤病理分级诊断及判断预后的重要参考依据,伴有癫痫的胶质瘤组织与不伴有癫痫相比HMGB1表达无差异,没有诊断价值。
Objective The expression of high mobility group box-1 (HMGB1) and its clinical significance in human glioma were evaluated. Methods The literatures on HMGB1 and glioma were obtained by retrieving databases such as Pubmed, Embase, Ovid, Chinese National Knowledge Infrastructure (CNKI). Meta-analysis was conducted by Revman 5.3 software. Results Eventually 7 case-control studies were enrolled. HMGB1 expression in glioma group versus control group detected by immunohistochemistry (IHC) [ Odds ratio (OR) = 26.53 ; 95 % confidence intervals ( C I) = 13.70 - 51.35 ; P 〈 0.01 ] and real-time fluorescence quantitative polymerase chain reaction (RT-PCR) [ mean difference(MD) = 16.55 ; 95% CI = 11.21 - 21.90 ; P 〈 0.01 ], and HMGB1 expression in glioma pathological grade ( OR = 0.53 ; 95% CI =0.31 -0.90; P =0.02) were all statistically significant. HMGB1 expression in glioma with epilepsy versus not with epilepsy was not significantly different ( OR = 5.32 ; 95% CI = 0.10 -293.11 ; P = 0.41 ). Conclusion HMGB1 expression is significantly higher than that in the control group, and it is related to the pathological grade of glioma, suggesting that HMGB1 is expected to be used as an important reference for the diagnosis and prognosis of glioma. There is no difference in the expression of HMGB1 between glioma with epilepsy and not with epilepsy.
出处
《中华神经外科疾病研究杂志》
CAS
2018年第1期23-26,共4页
Chinese Journal of Neurosurgical Disease Research
基金
国家自然科学基金资助项目(30471774)
陕西省自然科学基金资助项目(2003C1-16)